Transcranial Magnetic Stimulation (TMS) Clinic Offers Noninvasive Treatment For Major Depression

Article

Committing to the promise it holds, Rush University Medical Center psychiatrists are now putting into action transcranial magnetic stimulation, the first FDA-approved, non-invasive antidepressant device-based treatment that is clinically proven for depression treatment, making them among the first to test the technique after having helped develop it.

Committing to the promise it holds, Rush University Medical Center psychiatrists are now putting into action transcranial magnetic stimulation, the first FDA-approved, non-invasive antidepressant device-based treatment that is clinically proven for depression treatment, making them among the first to test the technique after having helped develop it.

With drug treatment options that are ineffective or intolerable for many patients due to side effects, and current therapies providing no benefit to at least one-third of depressed patients, TMS now provides a treatment options for those who have been left without adequate therapy.

By delivering highly focused magnetic field pulses to the left prefrontal cortex through repeated short bursts of magnetic energy that are introduce through the scalp, neurons become excited in the parts of the brain linked to depression.

"Patients receive treatment in an outpatient setting and are able to return to normal activities right away," said Dr. Philip Janicak, professor of psychiatry and lead investigator at Rush for the clinical trials of TMS. The 40-minute, outpatient procedure requires no anesthesia or sedation, with patients remaining awake and alert during each of the daily administrations that last for 4-6 weeks.

"TMS therapy is a safe and effective alternative for patients who suffer from major depressive disorder and are not getting satisfactory improvement from antidepressant medications," said Janicak.

Related Videos
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Depression Screening: Challenges and Solutions at the Primary Care Level
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
© 2024 MJH Life Sciences

All rights reserved.